Last reviewed · How we verify

TenNor Therapeutics (Suzhou) Limited — Portfolio Competitive Intelligence Brief

TenNor Therapeutics (Suzhou) Limited pipeline: 0 marketed, 0 filed, 3 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Clarithromycin placebo tablets Clarithromycin placebo tablets phase 3
Rifasutenizol capsules Rifasutenizol capsules phase 3 Rifamycin antibiotic Bacterial RNA polymerase (mycobacterial) Infectious Disease
Bismuth potassium citrate placebo capsules Bismuth potassium citrate placebo capsules phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bausch Health Americas, Inc. · 1 shared drug class
  2. Institute of Tropical Medicine, Belgium · 1 shared drug class
  3. Miguel Santín · 1 shared drug class
  4. National Institute of Allergy and Infectious Diseases (NIAID) · 1 shared drug class
  5. National Taiwan University Hospital · 1 shared drug class
  6. Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji · 1 shared drug class
  7. Seoul National University Hospital · 1 shared drug class
  8. South China Children's Leukemia Group · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for TenNor Therapeutics (Suzhou) Limited:

Cite this brief

Drug Landscape (2026). TenNor Therapeutics (Suzhou) Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tennor-therapeutics-suzhou-limited. Accessed 2026-05-17.

Related